Company news

Corbus Pharmaceuticals Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

May 26, 2020

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

May 21, 2020

Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates

May 10, 2020

Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020

May 3, 2020

Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology

April 28, 2020

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results

March 11, 2020

Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director

March 9, 2020

Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020

March 4, 2020

Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

February 10, 2020

Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

February 6, 2020

Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock

February 5, 2020

Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

November 17, 2019

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

November 10, 2019

Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates

November 6, 2019

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

October 2, 2019

Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA

April 17, 2019

Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors

April 7, 2019

← Newer news releases

Calls

Decks

The 5 newest of 45 decks. Every deck is listed under its year.